AP Rated to Sandimmune®* Unit-of-Use Bar-Coding
	Paddock Cyclosporine Injection, USP
	Strength	Size	NDC
	250mg/5mL	10 x 5 mL ampules	0574-0866-10

Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe cyclosporine.  Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.  The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.  Cyclosporine, when used in high doses, can cause hepatotoxicity and nephrotoxicity.  As in patients receiving other immunosuppressants, those patients receiving cyclosporine are at increased risk for development of lymphoma and other malignancies, particularly those of the skin.  Cyclosporine should not be used with other immunosuppressive agents except adrenal corticosteroids. Patients receiving cyclosporine injection should be under continuous observation for at least the first 30 minutes following the start of the infusion and at frequent intervals thereafter.  If anaphylaxis occurs, the infusion should be stopped.  An aqueous solution of epinephrine 1:1000 should be available at the bedside as well as a source of oxygen.